X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PFIZER - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PFIZER ASTRAZENECA PHARMA/
PFIZER
 
P/E (TTM) x 95.2 24.3 391.2% View Chart
P/BV x 13.6 3.9 350.4% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   PFIZER
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PFIZER
Mar-16
ASTRAZENECA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2852,724 47.2%   
Low Rs6341,611 39.4%   
Sales per share (Unadj.) Rs189.6440.9 43.0%  
Earnings per share (Unadj.) Rs-0.248.7 -0.4%  
Cash flow per share (Unadj.) Rs3.875.8 5.1%  
Dividends per share (Unadj.) Rs015.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs68.6462.9 14.8%  
Shares outstanding (eoy) m25.0045.75 54.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.9 102.9%   
Avg P/E ratio x-4,712.744.5 -10,587.4%  
P/CF ratio (eoy) x249.628.6 872.5%  
Price / Book Value ratio x14.04.7 298.6%  
Dividend payout %030.8 0.0%   
Avg Mkt Cap Rs m23,98899,163 24.2%   
No. of employees `0001.62.9 54.0%   
Total wages/salary Rs m1,6052,758 58.2%   
Avg. sales/employee Rs Th3,040.26,981.7 43.5%   
Avg. wages/employee Rs Th1,029.2954.5 107.8%   
Avg. net profit/employee Rs Th-3.3771.1 -0.4%   
INCOME DATA
Net Sales Rs m4,74020,170 23.5%  
Other income Rs m92857 10.7%   
Total revenues Rs m4,83221,028 23.0%   
Gross profit Rs m-1304,310 -3.0%  
Depreciation Rs m1011,239 8.2%   
Interest Rs m05 0.0%   
Profit before tax Rs m-1393,923 -3.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m13999 140.5%   
Tax Rs m51,794 0.3%   
Profit after tax Rs m-52,228 -0.2%  
Gross profit margin %-2.721.4 -12.8%  
Effective tax rate %-3.745.7 -8.0%   
Net profit margin %-0.111.0 -1.0%  
BALANCE SHEET DATA
Current assets Rs m2,72616,299 16.7%   
Current liabilities Rs m2,4357,594 32.1%   
Net working cap to sales %6.143.2 14.2%  
Current ratio x1.12.1 52.2%  
Inventory Days Days7465 113.0%  
Debtors Days Days4126 158.3%  
Net fixed assets Rs m1,0358,622 12.0%   
Share capital Rs m50458 10.9%   
"Free" reserves Rs m94220,722 4.5%   
Net worth Rs m1,71621,180 8.1%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,15629,137 14.3%  
Interest coverage xNM755.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.7 164.7%   
Return on assets %-0.17.7 -1.6%  
Return on equity %-0.310.5 -2.8%  
Return on capital %019.0 0.0%  
Exports to sales %5.70.1 9,582.1%   
Imports to sales %6.517.5 37.0%   
Exports (fob) Rs m27012 2,251.7%   
Imports (cif) Rs m3063,526 8.7%   
Fx inflow Rs m37552 725.3%   
Fx outflow Rs m470140 335.9%   
Net fx Rs m-96-88 108.2%   
CASH FLOW
From Operations Rs m-83,436 -0.2%  
From Investments Rs m-146-6,991 2.1%  
From Financial Activity Rs m862-619 -139.3%  
Net Cashflow Rs m709-4,174 -17.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 4.9 320.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.7 38.4%  
Shareholders   12,856 85,207 15.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   IPCA LABS  NOVARTIS  PANACEA BIOTECH  MERCK LTD  GSK PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 17, 2017 03:37 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS